All In Biotech

Drug Trial Radar · NCT06104839

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

73

Planned (sponsor's estimate)

Start

Sep 1, 2024

Primary completion

Oct 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
NEXTGEN BioscienceIndustry
Sponsor type
Industry
First posted
Oct 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Conditions

  • Alopecia Areata

Interventions

  • NXC736Drug

    oral administration

  • PlaceboDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change(%) in SALT score from baseline at Week 12Time frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital.

    Seoul, South Korea · Recruiting

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.